Trump Approves Plan to Oust FDA Chief Makary Amid Vaping, Drug and Abortion Disputes

President Donald Trump has signed off on a plan to remove Food and Drug Administration Commissioner Marty Makary, according to multiple reports citing administration sources. The move caps months of tension between the White House and a commissioner who positioned himself as a reformer battling Big Pharma, Big Food, and the bureaucratic inertia that has left American families sicker and more dependent on corporate medicine.

Makary, a Johns Hopkins surgeon who gained prominence for challenging the politicized public health regime during the COVID era, took over the FDA in early 2025 with backing from the Make America Healthy Again movement. He spoke openly about restoring what he called gold standard science, speeding honest drug reviews while standing up to industry pressure, and confronting the additives and ultra processed junk making children obese and unwell. In a recent interview he described the mission as taking politics out of the process and refusing to fear Big Pharma or Big Food. That approach won him praise from parents tired of watching federal agencies serve corporate balance sheets instead of public health.

Yet those same instincts created powerful enemies. Makary resisted fast tracking fruit flavored vapes blueberry, mango and similar varieties from manufacturer Glas, arguing the sweet tastes would clearly appeal to teenagers and younger children. President Trump, who campaigned on saving vaping and has watched his support among Gen Z collapse to a dismal 24 percent in recent polling, grew frustrated. The flavors were eventually approved after White House pressure, but the episode underscored a deeper rift. One side saw flavored nicotine products as an adult choice squeezed by overregulation. The other saw a cynical play to hook the next generation the same way sugary cereals and cartoon mascots hooked their parents.

Anti abortion advocates piled on for separate reasons. Groups like Susan B. Anthony Pro Life America demanded Makary's removal after the FDA approved a generic version of the abortion pill mifepristone, making the drug cheaper and easier to obtain. Marjorie Dannenfelser called the decision reckless and dangerous to women and girls. Makary responded that the FDA had committed to a serious, granular safety study on the drug, the kind of rigorous review that had been missing for years. That measured stance satisfied neither activists who wanted immediate restrictions nor industry allies who viewed any delay as regulatory hostility.

The discontent spread beyond those issues. Biotech firms and some conservative voices complained that Makary's team had rejected certain new drug applications and continued high turnover at the agency. Former Senator Rick Santorum accused him of replacing competent officials with holdovers who stifled innovation. Yet Makary's defenders point out he inherited an FDA hollowed out by years of revolving door leadership, where decisions too often followed political winds or corporate donations rather than evidence. His public profile, frequent media appearances, and alignment with Health Secretary Robert F. Kennedy Jr. on food dyes, vaccine skepticism, and chronic disease made him a lightning rod.

White House spokesman Kush Desai issued a standard defense, saying the administration remains focused on historic victories for the American people. Trump himself has not commented publicly on Makary's status, and those close to the situation caution the plan could still shift. The president has changed course on personnel before after Makary proved persuasive in earlier attempts to sideline him.

This brewing ouster reveals the difficult trade offs inside the Trump administration. On one hand, the president ran on shaking up captured institutions and delivering results for working families who can no longer afford to trust the so called experts. On the other, electoral math with young voters and pressure from well organized lobbying interests appear to be driving decisions that risk putting nicotine in the hands of children and maintaining easy access to powerful drugs without the long overdue safety scrutiny Makary advocated.

For millions of parents the core question is straightforward. Will federal health policy finally prioritize the next generation's physical wellbeing over polling data, industry profits, and ideological score settling? Makary's departure, if it happens, will test whether the Make America Healthy Again agenda was serious reform or just another slogan that dissolves when it collides with political reality. The FDA has spent decades serving powerful interests while ordinary Americans suffer rising chronic illness. Replacing a commissioner who at least tried to challenge that pattern should not be done lightly or for the wrong reasons.